Invitation to presentation of the Q1 Report 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4.
Investors, financial analysts, and media are invited to participate in a webcast and a following QnA session on May 4 at 09:00 (CET). The presentation will be hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and will be held in English. It will be published on the website of Oncopeptides in conjunction with the start of the presentation.
Information for participants
If you wish to participate in the webcast, please use the link below. Through the webcast you will have opportunities to ask written questions to the company´s leadership.
If you wish to participate via teleconference, please register on the link below. After the registration you will be provided with a phone number and a conference ID to access the conference. You can ask questions to the leadership verbally via the teleconference.
For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
Cell phone: + 46 70 262 96 28
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.